CTi Biopharma — Investor Presentation (January 2018)
27 slides from CTi Biopharma's investor presentation, Jan 5, 2018
Slide 1: Corporate Presentation January 2018
© Copyright 2017 CTI BioPharma Corp. All rights reserved. Corporate Presentation January 2018
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or a
Slide 3: CTI BioPharma
CTI BioPharma • Lead compound pacritinib (JAK2 inhibitor) - Seeks to address a significant unmet medical need in myelofibrosis - Focus on treating patients following ruxolitinib (Jakafi/Jakavi) therapy and/or with thrombocytopenia • Phase 2 dose-finding study (PAC203) on-going - Interim analysis exp
Slide 4: Focused and Well Financed: Key Milestones 2017
Focused and Well Financed Key Milestones 2017 • Corporate New management team members; 3 new independent Directors Projected year-on-year cost reductions Fundraising of $45mm in gross proceeds completed in July 2017 Major shareholders included BVF and OrbiMed • Pacritinib Removal of FDA cl
Slide 5: Our Pipeline – Hematology Focus
Our Pipeline – Hematology Focus 5 Program Indication Phase 1 Phase 2 Phase 3 Approved Pacritinib PERSIST-1: Myelofibrosis (all platelet counts) PERSIST-2: Myelofibrosis (platelets ≤100,000/µL) PAC203: Myelofibrosis, patients following ruxolitinib therapy1 PIXUVRI® (pixantrone) Relapsed Aggressive B-
Slide 6: Myelofibrosis
Myelofibrosis 6 Impaired Blood Cell Production Thrombocytopenia, Anemia Prevalence 20K 28K Malignant bone marrow cancer with median survival 6 years after diagnosis; only approved therapy is Jakafi/Jakavi (ruxolitinib) Vannucchi, ASH Education Book, 2011; SmartAnalyst Quantitative Web survey (N=120)
Slide 7: Pacritinib
Pacritinib • Second generation JAK2 specific inhibitor • Orphan drug designation for myelofibrosis in US and EU • Patent protection until 2026/2030 (plus term extension) Seeks to address unmet medical need in myelofibrosis patients with prior ruxolitinib treatment and/or thrombocytopenia 7
Slide 8: Pacritinib Market Opportunity
Pacritinib Market Opportunity Myelofibrosis Prevalence US/EU ~48K patients¹ Company estimates based on: 1. SmartAnalyst Quantitative Web survey (N=120); 2. 2015 ZS Pacritinib MD Treatment Flow US/EU5; 3. IMS Jakafi Prescription data Q3 2014; 4. 2017 Kantar Health MF Opportunity Assessment.8 Ruxoliti
Slide 9: Ruxolitinib Discontinuations
Ruxolitinib Discontinuations Poor survival following ruxolitinib discontinuation1,2 9 1. Newberry, Blood 2017; 2. Mehra, et al. ASH 2016 poster, Abstract 4769; 3. Cervantes, Blood 2012, Abstract 801; 4. Verstovek, Haematologica 2013. 50% of patients discontinue ruxolitinib by 3 years3,4 - Overall su
Slide 10: Thrombocytopenia and ruxolitinib
Significant and rapid decline in platelet counts with ruxolitinib at doses of 15-20mg BID1 1. Verstovsek, et al., Haematologica, 2015 May; 100(4): 479–488; 2. Ruxolinitib NDA Clinical Pharmacology and Biopharmaceutical Review(s), FDA 2011.10 ….associated with dose reductions ….which potentially redu
Slide 11: On-going PAC203 Clinical Trial
On-going PAC203 Clinical Trial 11 Pacritinib 100 mg BID Primary or secondary myelofibrosis Prior ruxolitinib therapy Randomization 1:1:1 Up to 105 patients Evaluate Safety and SVR at 12 and 24 weeks Pacritinib 100 mg QD Pacritinib 200 mg BID • Second-line dose ranging study as requested and agreed u
Slide 12: Rationale for PAC203 Clinical Trial
Rationale for PAC203 Clinical Trial • Identify the lowest effective dose of pacritinib • Evaluate safety and SVR at 12 and 24 weeks • Evaluate long-term exposure and safety data • Evaluate dosing flexibility 12
Slide 13: PERSIST-2 Phase 3 Myelofibrosis
SVR, spleen volume reduction; TSS, total symptom score; *Cross-over from BAT allowed after assessment of the primary endpoint at week 24, or after progression; ** BAT may include ruxolitinib at the approved dose per its label. Pacritinib 200 mg BID Primary MF, ET-MF or PV-MF Platelets ≤100,000/µL Pr
Slide 14: PERSIST-2: Efficacy Results
PERSIST-2: Efficacy Results 14 Endpoint Statistics PAC 200 mg BID (N=74) PAC 400 mg QD (N=75) PAC BID+QD (N=149) BAT (N=72) ≥35% SVR N (%) 16 (21.6) 11 (14.7) 27 (18.1) 2 (2.8) 95% CI 12.9-32.7 7.6-24.7 12.3-25.3 0.3-9.7 P value vs BAT 0.001 0.017 0.001 - Reduction of ≥50% TSS N (%) 24 (32.4) 13 (17
Slide 15: PERSIST-2: Efficacy Results in the Second-line Setting
PERSIST-2: Efficacy Results in the Second-line Setting 15 Efficacy Pac 200 mg BID (N=33) Pac 400 mg QD (N=33) BAT (N=34) ≥35% SVR 18% 6% 3% Reduction of ≥50% TSS 30% 12% 15% Patients previously treated with ruxolitinib demonstrated greater benefit with pacritinib versus BAT at 24 weeks SVR, ≥35% spl
Slide 16: PERSIST-2: Overall Survival
PERSIST-2: Overall Survival 16 Data censored at date of clinical hold; Mascarenhas J, et al., ASH 2016. Abstract LBA-5.
Slide 17: PERSIST-2: Adverse Events (≥15%)
PERSIST-2: Adverse Events (≥15%) 17 Adverse Event (%) PAC QD (N=104) PAC BID (N=106) BAT (N=98) Diarrhea 67 48 15 Nausea 38 32 11 Thrombocytopenia 33 34 23 Anemia 28 24 15 Vomiting 21 19 5 Fatigue 17 17 16 Peripheral Edema 13 20 15 Dizziness 14 15 5 Abdominal Pain 19 9 19 Pyrexia 11 15 3 Less GI tox
Slide 18: PERSIST-1 Phase 3 Myelofibrosis
Primary MF, ET-MF or PV-MF Any platelet count No prior treatment with JAK2 inhibitors 2:1 Randomization n = 327 Primary Endpoint ≥35% SVR at Week 24Best Available Therapy (BAT) excl. ruxolitinib Pacritinib 400 mg QD PERSIST-1 Phase 3 Myelofibrosis 18 • Multinational study in MF patients with any pla
Slide 19: PERSIST-1: Spleen Volume Reduction
PERSIST-1: Spleen Volume Reduction 19 ≥35% SVR at 24 weeks PAC BAT P-value Overall 19% (N=220) 5% (N=107) 0.0003 Platelets ≤100,000/µl 17% (N=72) 0% (N=34) 0.0086 ≤50,000/µl 23% (N=35) 0% (N=16) 0.045 *SVR, ≥35% spleen value reduction; Mesa RA, et al., Lancet Haematology 2017.
Slide 20: PERSIST-1: Adverse Events (>10%)
PERSIST-1: Adverse Events (>10%) 20 Adverse Event (%) PAC QD (N=220) BAT (N=106) Diarrhea 55 10 Nausea 27 7 Anemia 24 20 Thrombocytopenia 17 14 Vomiting 16 6 Fatigue 10 9 Abdominal Pain 10 9 Peripheral Edema 8 12 Pyrexia 5 10 Mesa RA, et al., Lancet Haematology 2017.
Slide 21: Regulatory Strategy and Target Timelines
Regulatory Strategy and Target Timelines FDA 21 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18 4Q18 EMA MAA submission D180 LoQD120LoQ CHMPOpinion PAC203 interim PAC203 final • Pacritinib seeks to address significant unmet medical needs in MF • Prior exposure to ruxolitinib (Jakafi/Jakavi) • Thrombocytopenia (platel
Slide 22: PIXUVRI: Approved in Europe
PIXUVRI: Approved in Europe • Conditional approval in 2012 • 3rd - 4th line aggressive B-cell NHL • Partnered with Servier (ex-US) 22 ® ( P I X A N T R O N E )
Slide 23: PIXUVRI: PIX306 Study
PIXUVRI: PIX306 Study Relapse after CHOP-R or an equivalent regimen and ineligible for stem cell transplant 1:1 Randomization Primary Endpoint: PFS Secondary Endpoints: CR, ORR, OS Gemcitabine Rituximab Pixantrone Rituximab Phase 3 post-marketing commitment study • Aggressive B-cell NHL or Follicula
Slide 24: Financial and Corporate
Financial and Corporate
Slide 25: Financial Overview
Financial Overview Capital Structure and Financial Statistics Exchanges NASDAQ and MTA: CTIC Shares Outstanding as of 9/30/17 ~43mm Cash as of 9/30/17 ~$52.8mm Debt as of 9/30/17 ~$14.8mm 25
Slide 26: Upcoming Milestones and Objectives
Upcoming Milestones and Objectives • Pacritinib - Submit responses to D120 LoQ (1Q 2018) - Interim analysis of PAC203 study (2Q 2018) - Complete enrollment of PAC203 study (2H 2018) - CHMP opinion (mid-2018) • Pixuvri - Top-line data on PIX306 (1H 2018) 26
Slide 27: Company Contact
Company Contact: David Kirske, CFO [email protected]